James D. Thacker

Company: Therimunex Pharmaceuticals, Inc.

Job title: Founder, Head of Discovery & Science

Seminars:

The NLRP3 Inflammasome is a Therapeutic Target for Precision Medicine in Chronic Inflammatory Diseases: Fibrosis to Cancer 3:00 pm

An NME drug homolog of the NLRP3 regulator Chronic inflammatory disease platform Therapeutic relevance in cancerRead more

day: Day 2 - Track B - Afternoon